Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
Company Profile
Latest Presentation
Industry Classifications
Sector:
Healthcare
Industry:
Medical Devices & Instruments
NAICS:
In-Vitro Diagnostic Substance Manufacturing (325413)
SIC:
Electromedical And Electrotherapeutic Apparatus (3845)
Contact Information
Investor Relations
Michael Parks
Vice President of Investor Relations
M: 484-356-7105
mep@pavmed.com
Company Contact
Lucid Diagnostics Inc.
One Grand Central
60 East 42nd Street, Suite 4600
New York, NY 10165
T: 212-949-4319
info@luciddx.com